Nanoparticle Strategy Targets Cancer Cells Using Tumors’ Copper

Researchers have advanced a nanoparticle-based strategy to improve cancer treatment by utilizing the copper supply within tumors. This approach, spearheaded by Guizhou Medical University and detailed in Biomedical Analysis, leverages cuproptosis. This form of cell death arises when copper disrupts cancer cell survival. Until now, treatments have relied on external copper, raising toxicity concerns for healthy tissues.

The innovative method circumvents this issue by delivering a copper-binding agent directly to cancer cells, using copper already in tumors. Researchers engineered biodegradable nanoparticles from PLGA-PEG, a safe material that breaks down in the body. They enhanced the nanoparticle surface with iRGD, a peptide that aids in targeting cancer cells. These nanoparticles carry TPEN, which binds to copper ions.

The formulation TPEN@1%-iPPN targets tumor cells, as proven in lab tests. The nanoparticles, around 80 nanometers in size, remained stable in bloodlike conditions. They gradually released TPEN over 72 hours, allowing sustained exposure to the tumor environment.

Experiments on 4T1 breast cancer cells demonstrated the iRGD-coated nanoparticles had higher uptake in cancer cells compared to non-targeted ones. A 1% iRGD modification provided optimal targeting and particle stability. Studies also confirmed the targeted nanoparticles’ increased toxicity to cancer cells, while limiting damage to normal cells. TPEN@1%-iPPN showed less harm to human endothelial cells compared to untargeted TPEN.

Dr. Ying Chen, the study’s corresponding author, expressed hopes for more research into cuproptosis-based nanomedicine, noting the reduced systemic side effects of mobilizing endogenous copper. Experts believe this technique, although promising, faces hurdles before it can become a viable treatment. Dr. Harshad Kulkarni of BAMF Health highlighted its potential to exploit cancer’s metabolic vulnerabilities. He emphasized the need for safety and efficacy proof, suitable cancer identification, and biomarkers of treatment effectiveness.

The central challenge, as he stated, is ensuring tumor selectivity since copper is crucial for normal cellular operations. Altering copper levels body-wide might cause toxicity. Future studies must assess these side effects and cancer cells’ adaptability to copper handling. While the approach might benefit breast cancer and more, tumor characteristics dictate success more than cancer location. Continued research is essential to transform this lab approach into a patient-safe treatment.